A ViiV Healthcare combination HIV drug that aims to deliver three HIV treatments in a single tablet has been has been submitted to U.S. regulators for approval.

ViiV, a joint venture formed by GlaxoSmithKline (NYSE:GSK) and Pfizer (NYSE:PFE), developed the investigational treatment, which combines HIV drugs dolutegravir, abacavir and lamivudine in a single tablet. ViiV’s dolutegravir was approved by the Food and Drug Administration in August and is marketed under the brand name Tivicay.

ViiV already markets a drug that combines two of those treatments, abacavir and lamivudine. GSK received FDA approval on that drug, marketed under the name Epzicom, in 2004. The drug is also available in Europe under the name Kivexa.

ViiV said that a marketing authorization application for this single-tablet drug regimen combining the three HIV treatments will be submitted “in the near future.”

“People living with HIV and their doctors seek to use appropriate treatment options for the individual, while also trying to minimize the number of pills required for effective and acceptable antiretroviral treatment,” ViiV Chief Medical Officer John Pottage said in a statement.“This submission aims to make a complete Tivicay-based regimen available for the first time in a single once-daily pill.”

London-based ViiV maintains its U.S. operations on GSK’s campus in Research Triangle Park.